Shares of Stantec Inc. (TSE:STN – Get Free Report) (NYSE:STN) have earned an average rating of “Buy” from the ten analysts that are currently covering the firm, Marketbeat.com reports. Ten equities research analysts have rated the stock with a buy recommendation. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is C$143.00.
STN has been the topic of a number of recent research reports. Scotia dropped their target price on Stantec from C$133.00 to C$129.00 and set a “sector outperform” rating on the stock in a research report on Friday, August 14th. Scotiabank reduced their price target on Stantec from C$138.00 to C$133.00 and set a “sector outperform” rating for the company in a research report on Friday, July 10th. Desjardins set a C$169.00 price target on shares of Stantec and gave the stock a “buy” rating in a research note on Friday, August 14th. Canadian Imperial Bank of Commerce lowered their price objective on shares of Stantec from C$160.00 to C$137.00 and set an “outperformer” rating on the stock in a report on Wednesday, July 8th. Finally, ATB Cormark Capital Markets boosted their price objective on shares of Stantec from C$130.00 to C$133.00 and gave the stock an “outperform” rating in a research report on Friday, August 14th.
Get Our Latest Analysis on Stantec
Insider Activity at Stantec
In other Stantec news, Director Shelley Ann Marie Brown acquired 393 shares of the company’s stock in a transaction on Thursday, October 1st. The shares were purchased at an average price of C$95.91 per share, for a total transaction of C$37,692.63. Following the completion of the purchase, the director directly owned 6,277 shares of the company’s stock, valued at approximately C$602,027.07. This represents a 6.68% increase in their ownership of the stock. Also, Director Susan Reisbord purchased 2,068 shares of the business’s stock in a transaction on Monday, August 24th. The shares were acquired at an average cost of C$102.59 per share, with a total value of C$212,156.12. Following the acquisition, the director directly owned 8,253 shares in the company, valued at approximately C$846,675.27. The trade was a 33.44% increase in their ownership of the stock. 0.27% of the stock is owned by insiders.
Stantec Stock Performance
Shares of Stantec stock opened at C$106.79 on Thursday. Stantec has a 52 week low of C$93.15 and a 52 week high of C$158.13. The firm has a fifty day moving average of C$98.81 and a two-hundred day moving average of C$110.37. The company has a debt-to-equity ratio of 80.98, a quick ratio of 1.46 and a current ratio of 1.50. The stock has a market capitalization of C$12.18 billion, a price-to-earnings ratio of 24.11, a PEG ratio of 1.46 and a beta of 0.78.
Stantec (TSE:STN – Get Free Report) (NYSE:STN) last released its quarterly earnings data on Wednesday, August 12th. The company reported C$1.61 earnings per share for the quarter. The business had revenue of C$2.23 billion for the quarter. Stantec had a net margin of 6.23% and a return on equity of 15.26%.
Stantec Announces Dividend
The business also recently disclosed a quarterly dividend, which was paid on Thursday, October 15th. Stockholders of record on Thursday, October 15th were issued a $0.2450 dividend. The ex-dividend date was Tuesday, September 29th. This represents a $0.98 annualized dividend and a dividend yield of 0.9%. Stantec’s dividend payout ratio (DPR) is presently 21.22%.
Stantec Company Profile
Stantec empowers clients, people, and communities to rise to the world’s greatest challenges at a time when the world faces more unprecedented concerns than ever before. We are a global leader in sustainable engineering, architecture, and environmental consulting. Our professionals deliver the expertise, technology, and innovation communities need to manage aging infrastructure, demographic and population changes, the energy transition, and more. Today’s communities transcend geographic borders.
Featured Stories
- Five stocks we like better than Stantec
- AbbVie’s Humira Era Is Fading, But Its New Growth Engines Face Another Test
- GLP-1 Focus or Broader Peptide Exposure: Which ETF Has the Edge?
- Mortgage Rates Froze U.S. Housing, But These 3 Overseas Markets Still Pay Double Digits
- Big Tech Is Spending Billions on AIāThese 5 Stocks Are Getting Paid
Receive News & Ratings for Stantec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stantec and related companies with MarketBeat.com's FREE daily email newsletter.
